Clinical trial
Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate…
NCT00058539 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00058539 |
|---|---|
| Title | Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer |
| Official title | A Phase II, Open-Label, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Omnitarg (Pertuzumab) in Subjects With Castration-Resistant Prostate Cancer |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | rhuMAb 2C4 (pertuzumab) |
| Enrollment | 42 |
| Start date | Apr 1, 2003 |
| Primary completion | Oct 1, 2004 |
| Completion | Oct 1, 2004 |
| First posted | Apr 9, 2003 |
| Last update posted | Jun 23, 2015 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: